CLINICAL TRIALS PROFILE FOR METHYLPREDNISOLONE SODIUM SUCCINATE

All Clinical Trials for Methylprednisolone Sodium Succinate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000579 ↗	Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-09-01	The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00097448 ↗	Sudden Deafness Treatment Trial	Completed	National Institute on Deafness and Other Communication Disorders (NIDCD)	Phase 3	2004-12-01	This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours).
NCT00097448 ↗	Sudden Deafness Treatment Trial	Completed	Massachusetts Eye and Ear Infirmary	Phase 3	2004-12-01	This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours).
NCT00185692 ↗	Allogeneic Transplantation From Related Haploidentical Donors	Completed	Stanford University	Phase 2	2000-08-01	The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
NCT00290602 ↗	Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome	Completed	National Cancer Center, Korea	Phase 2	2004-02-01	The purpose of this study is to determine whether the 2mg/kg administration of corticosteroids, in the form of methylprednisolone sodium succinate, in early phase acute respiratory distress syndrome after thoracic surgery, will reduce the postoperative mortality.
NCT00295269 ↗	Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1997-03-01	The purpose of this study is to assess innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS.

Clinical Trial Conditions for Methylprednisolone Sodium Succinate

Condition Name

Condition Name for Methylprednisolone Sodium Succinate
Intervention	Trials
Leukemia	3
Lung Diseases	2
Acute Respiratory Distress Syndrome	2
Spinal Cord Injuries	2

Condition MeSH

Condition MeSH for Methylprednisolone Sodium Succinate
Intervention	Trials
Syndrome	6
Graft vs Host Disease	4
Leukemia	4
Respiratory Distress Syndrome, Adult	3

Clinical Trial Locations for Methylprednisolone Sodium Succinate

Trials by Country

Trials by Country for Methylprednisolone Sodium Succinate
Location	Trials
United States	85
China	28
Canada	9
Australia	5
New Zealand	2

Trials by US State

Trials by US State for Methylprednisolone Sodium Succinate
Location	Trials
California	6
Massachusetts	4
Maryland	4
Texas	3
North Carolina	3

Clinical Trial Progress for Methylprednisolone Sodium Succinate

Clinical Trial Phase

Clinical Trial Phase for Methylprednisolone Sodium Succinate
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	4
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Methylprednisolone Sodium Succinate
Clinical Trial Phase	Trials
Completed	19
RECRUITING	8
NOT_YET_RECRUITING	6

Clinical Trial Sponsors for Methylprednisolone Sodium Succinate

Sponsor Name

Sponsor Name for Methylprednisolone Sodium Succinate
Sponsor	Trials
National Cancer Institute (NCI)	4
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2
Beijing Tiantan Hospital	2

Sponsor Type

Sponsor Type for Methylprednisolone Sodium Succinate
Sponsor	Trials
Other	96
NIH	8
UNKNOWN	7

Methylprednisolone Sodium Succinate Market Analysis and Financial Projection

Last updated: April 28, 2026

Methylprednisolone Sodium Succinate: Clinical Trials Update, Market Analysis, and 5-Year Projection

What is methylprednisolone sodium succinate’s current clinical development status?

Methylprednisolone sodium succinate (MPSS) is a long-established systemic corticosteroid supplied in injectable form (commonly described as IV/IM). Public trial activity is typically concentrated in:

• Acute indications where IV steroids are standard of care (e.g., neurologic, inflammatory, allergic, and pulmonary settings)
• Treatment regimens that compare steroid dosing schedules, timing, or adjunct therapies rather than inventing entirely new steroid mechanisms

However, no complete, actionable, up-to-date trial-by-trial dataset (study status, endpoints, enrollment, and top-line results) is available in the information provided here.
As a result, a precise “clinical trials update” by trial phase cannot be produced without risk of inaccuracy.

Where does the drug sit in the regulatory and commercial landscape?

MPSS is a mature, off-patent steroid in most markets, which shapes the commercial model:

• Price competition is structurally intense due to multiple manufacturers and generic availability.
• Channel focus typically targets hospital formularies, emergency/ICU dispensing, and payer contracting for injectable corticosteroids.
• Differentiation often occurs at the product level (packaging, concentrations, distribution reliability, and local regulatory approvals) rather than at the molecule.

Commercial implication: market growth is largely driven by utilization volume (acute care throughput, guideline adherence, and treatment incidence), not by premium pricing or new mechanism-led adoption.

---

Market analysis: Demand drivers, pricing dynamics, and competitive structure

What drives demand for MPSS injections?

Key utilization drivers for IV/IM methylprednisolone sodium succinate are:

• Hospital use in acute inflammatory and immune-mediated flares
• Neurologic indications where steroids are standard (commonly applied in multiple sclerosis-related relapses and optic neuritis protocols in many markets)
• Pulmonary and allergic severe presentations where IV steroids are used in escalation pathways
• Oncology supportive care where corticosteroids form part of multi-agent regimens in several disease settings

Demand mechanics in practice: MPSS use correlates with hospital admission volume, ED utilization, ICU throughput, and guideline-based steroid use in acute protocols.

How does pricing behave in this category?

For mature injectable generics, pricing typically follows:

• Downward pressure after generic entry and tender cycles
• Contract-based price ceilings via group purchasing organizations (GPOs) or national procurement tenders
• Formulary concentration where one or two low-cost suppliers win large hospital lots

Outcome: revenue growth typically tracks volume more than unit price.

Who competes with MPSS?

Competition is usually split into:

• Generic MPSS from multiple manufacturers
• Other corticosteroid injectables that can substitute clinically (e.g., prednisolone-based regimens, dexamethasone formulations, hydrocortisone depending on indication and clinician preference)

Substitution risk: if clinical protocols accept alternative steroids, procurement can shift to the lowest-tender options.

---

5-year market projection: Scenarios, volume logic, and revenue direction

What is the baseline projection framework for a mature injectable like MPSS?

Because the molecule is mature and pricing is pressured, projection logic should follow:

1. Utilization growth (driven by incidence and hospital access trends)
2. Formulary retention and tender outcomes (share shifts among generic suppliers)
3. Generic price erosion (margin compression rather than topline collapse in volume-heavy markets)

Projected market direction (high-level)

A clean numeric forecast cannot be produced from the information provided here because it requires:

• Current global and regional market size for MPSS (injectable corticosteroid segment)
• Current unit pricing or average selling price (ASP) benchmarks by geography
• Competitive tender-share and volume estimates
• Country-level incidence and hospital utilization metrics

Without these inputs, any specific numeric projection would be unreliable.

---

Actionable business takeaways

What should R&D, BD, and investment teams conclude?

• Clinical innovation is unlikely to be mechanism-led for MPSS; competitive advantage usually comes from product-level execution (supply reliability, packaging, contracting) rather than new clinical paradigms.
• Commercial upside is volume-led, not price-led. Strategy should focus on procurement access, hospital formulary positioning, and tender readiness.
• Substitution risk is real. Protocol flexibility among corticosteroid choices means commercial plans must account for class-level interchangeability.

---

Key Takeaways

• MPSS is a mature injectable corticosteroid with a market shaped by generic competition and hospital procurement cycles.
• A trial-by-trial clinical update with verified current status cannot be stated from the provided information without risking inaccuracies.
• Market growth, where it occurs, is typically utilization-driven, while pricing follows tenders and generic erosion.
• Competitive differentiation is most often execution-based (supply, contracting, product availability) rather than molecule differentiation.

---

FAQs

1. Is methylprednisolone sodium succinate still actively used clinically?
   Yes. IV/IM corticosteroid use remains standard in multiple acute inflammatory and immune-mediated settings.

2. What type of clinical trials are most common for MPSS now?
   Trials often compare dosing schedules, timing, endpoints, or adjunct therapy combinations rather than testing a new mechanism.

3. Does MPSS have patent protection-driven growth potential?
   Generally no. In most markets, growth is not driven by patent exclusivity due to generics.

4. What determines market share for MPSS in hospitals?
   Tender outcomes, formulary placement, supplier reliability, and total cost of care.

5. What is the biggest commercial risk for an MPSS supplier?
   Formulary substitution to alternative corticosteroids and aggressive generic tender pricing.

---

References

[1] No sources were provided in the prompt, and no external trial or market datasets were included in the information available to generate a cited, specific clinical update or numeric market projection.